secwatch.observer — SEC 8-K summary
======================================

Issuer:     Century Therapeutics, Inc. (IPSC)
CIK:        0001850119
Form:       8-K
Filed at:   2026-03-12T23:59:59+00:00
Accession:  0001104659-26-026761
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Century Therapeutics FY2025 net loss $9.6M; $135M placement extends cash into Q1 2029
--------------------------------------------------------------------------------

- Net loss of $9.6M improved from $126.6M in 2024; collaboration revenue from BMS rose to $109.2M (from $6.6M).
- Cash, cash equivalents, and securities $117.1M at Dec 31, 2025; with $135M Jan 2026 placement, runway extended to Q1 2029.
- CNTY-813 (T1D beta islet therapy) IND submission expected Q4 2026; initial clinical data anticipated 2H 2027.
- CNTY-308 (CD19-targeted CAR-iT) on track for clinical entry in 2026; CARAMEL IST data expected later this year.
- Strengthened balance sheet via oversubscribed $135M private placement led by TCGX; new board members appointed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850119/000110465926026761/0001104659-26-026761-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850119/000110465926026761/tm268574d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-026761

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer